-
The role of IL-18 in health and disease(Post)
Exploring IL-18: A key cytokine in inflammation and disease. Key Takeaways: IL-18, a pro-inflammatory cytokine, plays a pivotal role in immune responses, particularly in inducing Type II
VEGF-A VEGFR-2 Signaling: Decoding the Blueprint of Angiogenesis for Therapeutic Insights(Post)The orchestration of angiogenesis, the process by which new blood vessels form from pre-existing ones, is a complex symphony regulated by various molecular players. At the forefront of this int
Mast Cells IgE and Type 2 Immunity(Page) Diabetic Nephropathy & Diabetic Mellitus(Post)Overview of Diabetes Mellitus Diabetes mellitus (DM) is a major epidemic that affects over 347 million people worldwide (Danaei et al. 2011). The World Hea
Kundenspezifischer ELISA für Forschende, Checkliste und 4–12 Wochen(Post)Ein kundenspezifischer ELISA ist die richtige Wahl, wenn kein Katalogkit Ihre Zielmatrix, Spezies oder Sensitivität abdeckt. Am Ende steht kein Standardprodukt, sondern ein validierter Assay mit d
Complement: The Brake Matters More Than the Trigger(Post)Complement is firing on your own cells right now. Not in response to anything — C3 hydrolyses spontaneously in plasma at a low, constant rate, and every hydrolysed molecule is a potential convertase
Everything You Need to Know About Preeclampsia: A Guide(Post)Preeclampsia is a serious condition that can develop during pregnancy. It is marked by high blood pressure and the presence of protein in the urine and can cause serious problems for b
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
ELISA Troubleshooting: When Standards Read Below the Blank(Post)Quick answer On the GDF-6 (Growth Differentiation Factor 6) ELISA Kit, a researcher saw an elevated blank (OD ≈ 0.41) with the two lowest standards reading at or below it, and no signa
CD8+ T Cells: Understanding the Role of Cytotoxic T Cells in Immunity(Post)Immunology · T LymphocytesCD8+ T Cells: Cytotoxic Mechanisms, Memory and ExhaustionCD8+ T cells kill infected and transformed cells directly, and they do it with a specificity nothing else in the immu
VEGF: Inflammation and Tumourigenesis(Post)What is VEGF? Vascular Endothelial Growth Factors (VEGFs) are a group of homodimeric polypeptides, and are master regulators of vascular development, maintenance and a
Antibody-Drug Conjugates: Internalisation, Trafficking & the Bystander Effect(Page) Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor
Complete T Helper Cell Guide: Th1, Th2, Th17 & Functions(Post)The Th1 Pathway In this guide, we will explore the differences between TH1 and TH2 cells, their crucial roles in the immune system, and the contributions of cytokines and transcription f
Antibody Light Chains, Heavy Chains, Constant Regions & Tumour-Associated Antigens(Post)Immunology · Antibody BiologyAntibody Light Chains, Heavy Chains, Constant Regions & Tumour-Associated AntigensAn antibody’s specificity comes from its variable domains and its biological effect comes
NF-κB Signalling Pathway: Canonical and Non-Canonical Routes(Post)NF-κB is not one pathway, it is two clocks running at different speeds. The canonical arm fires within minutes of TNF-α, IL-1β or LPS reaching the surface, peaks, and is switched off by feedback it e
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
The PD-1 Pathway and Cancer Immunotherapy(Post)The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.
Cytokine neutralisation network(Page) Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha